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Augmentation by aprotinin of the renal response to vasopressin. We
contrasted the renal effects of vasopressin in Brattleboro rats with and
without pretreatment with aprotinin (20,000 KIU kg-'). In both treat-
ment groups, vasopressin injected at 3 mU kg' sec caused in conscious
rats elevation of urine osmolality and reduction of urine flow and
urinary excretion of total solutes. However, these effects of vasopressin
were significantly greater in aprotinin pretreated rats than in rats
without aprotinin treatment. In ketamine—pentobarbital—anesthetized
rats without aprotinin pretreatment, vasopressin infused at 2 mU kg'
hr' elevated urinary kinin excretion but did not affect urine flow rate
or osmolality; in contrast, in aprotinin—pretreated rats, the same dose of
vasopressin did not increase urinary kinins but caused elevation of
urinary osmolality and reduction of urine flow, solute excretion, and
glomerular filtration rate. Aprotinin pretreatment in anesthetized rats
also blunted the rise in kinin excretion elicited by vasopressin at a
higher dosage, 5 mU kg' hr', but did not potentiate the vasopres-
sin—induced antidiuresis. We conclude that aprotinin facilitates the
expression of the antidiuretic effect of vasopressin at a low, but not at
a high dosage. This effect of aprotinin may be a consequence of: (a)
renal kallikrein inhibition which prevents augmentation of renal kinins
in response to increased vasopressin levels, or (b) other unrecognized
properties of aprotinin.
suggested by reports that kinins promote the excretion of free
water in dogs receiving vasopressin [11] and decrease vasopres-
sin—stimulated water flow in the amphibian urinary bladder [12]
and in the rabbit cortical collecting tubule perfused in vitro [13].
Accordingly, renal kinins may be expected to attentuate vaso-
pressin induced antidiuresis.
If augmentation of renal kinins in response to increased
vasopressin levels contributes to minimize the associated
antidiuresis, inhibition of renal kinin generation should enhance
the antidiuretic effect of vasopressin. Therefore, the present
study was designed to contrast the renal effects of vasopressin
in diabetes insipidus rats with and without pretreatment with
aprotinin, an inhibitor of kallikrein and of other serine protein-
ases [14]. Aprotinin intensified the effectiveness of vasopressin
at low doses to produce antidiuresis and blocked the vasopres-
sin induced rise in kinin excretion.
Methods
General Procedure
Kinins are polypeptides released from a protein precursor,
kininogen, by plasma and tissue enzymes termed kallikreins [1].
In the kidney, kallikrein occurs in the cells of both the distal
convoluted tubule and the granular segment of the cortical
collecting tubule [2—4], nephron segments that also are reported
to contain kininogen [5]. Kinins resulting from the interaction of
kallikrein and kininogen within the kidney are added to the
tubular fluid of the distal nephron [6] and are excreted in the
urine, at a rate which presumably reflects the net balance
between the generation and the degradation of renal kinins [71.
Recently, a relationship between the renal kallikrein—kinin
system and vasopressin was inferred from observations that the
excretion of renal kinins is increased by the infusion of vaso-
pressin in man, dog, and rat [8—101. In agreement with a role for
vasopressin in promoting the activity of the renal kallikrein—
kinin system, we demonstrated that the urinary excretion of
kinins in the rat is positively correlated with the excretion rate
of vasopressin during conditions which increase or decrease the
secretion of the antidiuretic hormone [10]. Another dimension
of the relationship between renal kinins and vasopressin is
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Experiments were performed in male Brattleboro rats with
hereditary hypothalamic diabetes insidipus obtained from Blue
Spruce Farms (Altamont, New York, USA). Rats weighing 352
to 409 g were housed in a room with constant temperature
(24°C) and humidity (50%), and had free access to food and
water prior to the experiments. Two experimental protocols
were implemented.
In the first experimental protocol, 26 unanesthetized rats
were transferred to individual metabolism cages. They were
acclimated to the cages for four days and were then randomly
assigned to one of four treatment groups. Rats in groups 1 and
2 were injected subcutaneously with aprotinin (Trasylol,
Farbenfabriken Bayer, FRG) at about 1600 hours the day before
the experiment (50,000 KIU/rat), at 800 to 900 hours the day of
the experiment (25,000 KIU/rat), and again at 1100 to 1200
hours (25,000 KIU/rat) after completion of a three—hour control
urine sampling period. Rats in groups 3 and 4 were not treated
with aprotinin, receiving instead injections of saline vehicle (0.5
mi/rat) according to the treatment schedule described for
groups 1 and 2. Immediately after the third injection of aprotinin
or saline, 3.0 mU/rat of arginine vasopressin (Sigma Chemical
Co., St. Louis, Missouri, USA) was administered subcutane-
ously to rats in groups 1 (aprotinin—vasopressin group) and 3
(saline—vasopressin group), saline was administered to rats in
groups 2 (aprotinin—saline group) and 4 (saline—saline group),
and urine was sampled in all rats for another three hour period.
Water intake, urine volume, urine osmolality, and the excretion
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Table 1. Effect of vasopressin on renal function in conscious Brattleboro rats pretreated with aprotinin or with vehicle
Experimental group Control Vasopressin a Control Saline .°
Urine flow ,s.d min' kg'
Vehicle 414 27 158 13" —256 21 396 38 389 30 —7 2.7
Aprotinin 398 27 98 8'° —300 24 308 33 298 39 10 2.6
Urine osmolality mOsm kg-I of H20
Vehicle 215 12 366 14' 151 41 248 8 256 7 8 7
Aprotinin 228 14 443 21b,c 215 17C 268 10 271 7 3 6
Sodium excretion p.Eq miir' kg'
Vehicle 10.3 0.6 5.8 0.7" —4.5 0.6 9.8 1.1 10.3 1.9 0.5 7.8
Aprotinin 9.7 0.5 3•7 O.4° —6.0 0.5 9.3 2.0 7.9 1.7 —1.4 1.5
Potassium excretion pEq mi,r' kg'
Vehicle 12.6 0.8 7.2 07b —5.4 0.8 12.2 1.0 11.4 1.1 —0.8 0.8
Aprotinin 12.2 0.8 55 05b —6.6 0.6 9.8 2.1 10.0 1.8 0.2 1.0
Total solute excretion iiOsm min' kg'
Vehicle 84.6 4.6 55.4 43b —29.2 3.5 98.4 10.0 99.6 9.6 1.2 6.7
Aprotinin 84.9 4.6 41.3 2.9"'° —43.6 37C 81.2 18.0 80.8 12.0 —0.4 8.1
Water intake pi min' kg-I
Vehicle 420 30 180 20" —240 11 440 30 410 30 —30 29
Aprotinin 460 40 200 20" —260 14 460 40 470 50 10 43
Values are means SE of 26 observations.
a represents the difference between control values and vasopressin or saline
b p < 0.05 relative to control
c p < 0.05 relative to corresponding value in vehicle pretreated rats.
of sodium, potassium and total solutes were determined before
and after the administration of vasopressin or its saline vehicle.
This experimental protocol was repeated four times on different
days so that each rat was exposed to all four treatments.
In the second experimental protocol, 24 rats were anesthe-
tized by injections of ketamine (60 mg kg', i.m.) and sodium
pentobarbital (40 mg kg') and placed on a thermostatically
controlled board to maintain body temperature at 36 to 37°C.
After tracheostomy, cannulas were placed in the femoral veins
for infusion and administration of drugs, in the femoral artery
for measurement of blood pressure and blood sampling, and in
the bladder for quantitative collection of urine. Urine was
collected in pre-weighed polypropylene tubes maintained at
4°C. All urine samples were tested for contamination with blood
(Hemostix, Ames Co., Elkhart, Indiana, USA). Urine collec-
tions containing blood were discarded. All the rats received
continuous i.v. infusions of a 2:1 mixture of 0.9% saline and
2.5% dextrose (6.0 mllhr), and of methoxy-3H-inulin (1.5 Ci/hr
in 1.5 ml) in saline—dextrose solution. Blood samples (200 pi)
were collected at the midpoint of urine collection periods for
measurement of hematocrit and plasma inulin concentration.
The animals so prepared were distributed randomly into four
groups. Rats in groups 2 and 4 received i.v. infusions of
aprotinin (20,000 KIUIkg) over a 20 minute period, whereas rats
in groups 1 and 3 were given saline vehicle only. Following a
45-minute equilibration interval, a control urine sample was
collected over a 45 to 60 minute period. A continuous infusion
of vasopressin was then begun at a rate of 2.0 mU kg hC' in
rats of groups 1 and 2 and at 5.0 mU kg' h' in rats of groups
3 and 4; 30 minutes later, urine was collected for an additional
45 to 60 minute period. Urine flow, urine osmolality, and the
urinary excretion rate of sodium, potassium, total solutes,
kinins, and prostaglandin E2 (PGE2) were determined before
and after the administration of vasopressin. Glomerular filtra-
tion rate, as estimated by the clearance of tritiated inulin, was
derived from the concentrations of radioactive inulin in urine
and plasma.
Analytical procedures
Osmolality was measured in a microosmometer (Precision
Systems, Inc., Subury, Massachusetts, USA). The concentra-
tion of sodium and potassium in urine was determined by flame
photometry. The concentration of kinins [10] and PGE2 [15] in
urine was measured by radioimmunoassay after extraction as
previously described.
Data are presented as mean SE. The data were analyzed by
analysis of variance followed by Newman—Keul's a posteriori
test. The significance of differences in vasopressin—induced
changes between rats with and without aprotinin pretreatment
was determined by unpaired Student's t-test. The null hypoth-
esis was rejected when the P value was less than 0.05.
Results
Shown in Table 1 are the renal effects of vasopressin at 3 mU
kg in conscious Brattleboro rats pretreated with aprotinin or
with vehicle. Before vasopressin the values of water intake and
of urine flow, osmolality, electrolyte and solute excretions in
rats receiving aprotinin did not differ significantly from corre-
sponding values in vehicle treated controls. The administration
of vasopressin caused in both groups of rats an elevation of
urine osmolality and a reduction of water intake, urine flow, and
urinary excretions of sodium, potassium and total solute. In
animals pretreated with aprotinin, however, the vasopressin
induced elevation of urine osmolality and reduction of urine
flow and total solute excretion was significantly greater than in
rats treated with vehicle only. Consequently, rats treated with
aprotinin exhibited after vasopressin administration a higher
urine osmolality and a lower urine flow and total solute excre-
tion than did vehicle treated controls after vasopressin.
Aprotinin treated animals also manifested after vasopressin a
lower urinary sodium excretion than did vehicle treated con-
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Table 2. Effects of vasopressin infusion at 2 mU kg hr' in anesthestized Brattleboro rats pretreated with aprotinin or with vehicle
Experimental group Control Vasopressin b.a
Mean blood pressure mm Hg
Vehicle(N= 6) 120±2 122± 3 —2±3
Aprotinin(N = 6) 117 3 120 2 3 4
Hematocrit (%)
Vehicle (N = 6) 46.7 0.7 46.2 0.7 —0.5 0.6
Aprotinin (N = 6) 47.1 0.7 46.5 0.8 —0.6 0.5
Urine flow uJ mi,r1 kg'
Vehicle (N = 6) 264 20 230 25 —34 22
Aprotinin (N = 6) 350 39 163 17b.c —187 23C
Urine osmolality mOsm kg' of 1120
Vehicle (N = 6) 352 25 318 32 —34 25
Aprotinin (N = 6) 284 20 411 35 127 25c
Sodium excretion p.Eq mi,r' kg-I
Vehicle (N = 6) 12.4 1.7 13.3 2.6 0.9 2.9
Aprotinin (N = 6) 13.2 3.8 9.0 1.7 —4.2 2.7
Potassium excretion pEq min' kg'
Vehicle (N = 6) 10.3 1.6 9.6 0,6 —0,7 1.9
Aprotinin(N = 6) 11.7 1.6 8.5 10b —3.2 1.1
Total solute excretion p0sm min' kg'
Vehicle (N = 6)
Aprotinin (N = 6)
90.8 2.5
97.6 9.0
80.4 6.9
65.1 5,1b
—10.4 6.4
—32.5 5,7c
Glomerular filtration rate jsl mi,r' kg'
Vehicle (N = 6) 8433 272 8166 155 —317 316
Aprotinin (N = 6) 8567 353 6481 507 —2086 316C
Urinary kinin excretion pg min1 kg-I
Vehicle(N=4) 23±3 46±3k' 23±3
Aprotinin (N = 4) 15 i 14 2C —l 1
Urinary PGE2 excretion pg min' kg'
Vehicle (N = 6) 60 11 83 21 23 14
Aprotinin(N = 6) 77 9 87 12 10 20
Values are means se. N = number of experiments. The dose of aprotinin was 20,000 KIU/Kg, i.v.
a was obtained by subtracting the control period values from the vasopressin period values.
b p < 0.05 relative to control
P < 0.05 relative corresponding values to vehicle pretreated rats
trols after vasopressin. Values of water intake, urine flow and
osmolality, and excretion of electrolytes and total solute did not
change significantly with time in the two groups of rats that
were treated with aprotinin or vehicle but were not given
vasopressin.
The renal effects of intravenous vasopressin infusion at 2 mU
kg hr' in anesthetized rats pretreated with aprotinin or with
vehicle are shown in Table 2. In rats without aprotinin treat-
ment, vasopressin increased urinary kinin excretion by twofold,
but had no significant effect on arterial blood pressure and
hematocrit, glomerular filtration rate, urine flow and osmolality,
or urinary excretions of sodium, potassium, total solutes, and
PGE2. In contrast, in rats pretreated with aprotinin, the infusion
of vasopressin did not increase urinary kinin excretion but
increased urine osmolality and reduced urine flow, glomerular
filtration rate, and the urinary excretion of potassium and total
solutes.
Table 3 contrasts the renal effects of vasopressin infused at a
higher rate, 5 mU kg' hr', in anesthetized rats pretreated
with aprotinin or with vehicle. Vasopressin increased urinary
kinin excretion in rats pretreated with saline vehicle but not
with aprotinin, but caused comparable elevation of urine
osmolality in both groups of animals. Vasopressin also caused
in both groups of rats elevation of urinary PGE2 excretion and
lowering of glomerular ifitration rate, urine flow, and urinary
excretion of total solutes and sodium; these effects of vasopres-
sin in rats pretreated with aprotinin tended to exceed those in
animals without aprotinin pretreatment, but the differences are
not statistically significant.
Discussion
This study demonstrates that, in Brattleboro rats with diabe-
tes insipidus, pretreatment with aprotinin blunts the increase in
urinary kinin excretion elicited by vasopressin and facilitates
the expression of the antidiuretic effect of vasopressin at 2 mU
kgt hC' in anesthetized animals and at 3 mU kg in conscious
animals. However, pretreatment with the kallikrein inhibitor
did not potentiate the antidiuretic effect of vasopressin in
anesthetized rats at a higher dosage, 5 mU kg' hr ',a finding
that is in agreement with the results of a study by other
investigators [16]. Relative to this point, it is known that
Brattleboro rats are impaired in their ability to maximally
concentrate urine during short term vasopressin administration
[17]. Accordingly, aprotinin may be ineffective in potentiating
the antidiuretic effect of vasopressin at 5 mU kg' hC' if at
such dosage vasopressin alone elicits a response which is close
to the plateau of its dose response relationship.
A priori, the increased antidiuretic effect of vasopressin at
low doses in aprotinin treated rats may be the result of one or
more renal functional alterations, including decreased distal
nephron delivery of tubular fluid, magnification of the longitu-
dinal renal osmotic gradient, and/or facilitation of the stimula-
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Table 3. Effects of vasopressin infusion at 5 mU kg' hr' in anesthestized Brattleboro rats pretreated with aprotinin or with vehicle
Experimental group Control Vasopressin i
Mean blood pressure mm Hg
Vehicle (N = 6) 122 5 125 2 3 4
Aprotinin(N = 6) 122 6 120 2 —2 5
Hematocrit (%)
Vehicle (N = 6) 46.3 1.2 45.5 1.5 —0.8 0.5
Aprotinin (N = 6) 48.5 1.1 47.8 1.0 —0.7 0.6
Urine flow ,&d min' kg'
Vehicle (N = 6) 301 19 126 11b —175 22
Aprotinin (N = 6) 346 24 109 21b —237 24
Urine osmolality mOsm kg' of 1120
Vehicle (N = 6) 306 30 565 42" 259 28
Aprotinin (N = 6) 317 23 593 67b 276 62
Sodium excretion p.Eq min' kg'
Vehicle (N = 6) 19.1 2.8 11.9 1.4" —7.2 2.8
Aprotinin (N = 6) 22.1 3.3 10.5 2.7" —11,6 2.3
Potassium excretion pEq miir' kg'
Vehicle (N = 6) 11.0 1.2 7,4 1,3b —3.6 1.0
Aprotinin(N = 6) 11.5 1.0 7,7 12b —3.8 0.5
Total solute excretion p0sm min kg-i
Vehicle (N = 6) 90.7 8.2 67.7 4.9" —23.0 9.9
Aprotinin (N = 6) 109.4 8.6 60.8 6,4b —48.6 7.1
Glomerular filtration rate d min' kg_i
Vehicle (N = 4) 7589 752 6726 806b —863 138
Aprotinin (N = 4) 8634 702 7021 404 —1613 619
Urinary kinin excretion pg min' kg'
Vehicle(N= 4) 33±4 97±14" 64±13
Aprotinin (N = 4) 19 1C 17 7C —2 6C
Urinary PGE2 excretion pg min kg_i
Vehicle (N = 4) 63 9 175 22b 112 30
Aprotinin (N = 4) 62 6 120 15" 58 14
Values are means sa. The dose of aprotinin was 20,000 KIU/kg, i.v.
a was obtained by subtracting the control period values from the vasopressin period values.
b P < 0.05 relative to control
P < 0.05 relative to corresponding values in vehicle treated rats
tory action of vasopressin on water permeability in the collect-
ing tubules. For example, in our study the increased antidiuretic
effect of vasopressin at 2 mU kg' hr1 in anesthetized rats
coincided with a reduction of the rate of glomerular filtration to
about 75% of control; such a reduction would decrease distal
nephron delivery of tubular fluid, thereby limiting renal water
excretion. Additionally, aprotinin was reported to reduce the
blood flow to the renal medulla [18] and, consequently, is likely
to reduce the amount of solute that is carried away from the
medullary interstitium, resulting in augmentation of the osmotic
gradient. Aprotinin may also magnify the renal osmotic gradient
by amplifying the action of vasopressin to promote tubular
reabsorption of electrolytes and other solutes in diabetes
insipidus rats [19, 201. Pertaining to this point, in the present
study we found that aprotinin magnified in conscious and in
anesthetized rats a vasopressin—induced reduction of total
solute excretion. With regard to the possibility that aprotinin
facilitates the vasopressin—induced water permeability response
in collecting tubules, this agent was reported to increase both
vasopressin— and the cAMP-stimulated water flow in the blad-
der of Dominican toads [21]. However, this effect of aprotinin
seems to be species dependent as it was not observed in either
Mexican or Puerto Rican toads [22].
The effect of aprotinin in facilitating the expression of the
antidiuretic action of vasopressin in our studies may be due to
inhibition of renal kallikrein, inhibition of renal enzymes other
than kallikrein, or other unrecognized properties of the agent.
Pertaining to these points, aprotinin is known to inhibit protein-
ases other than kallikrein [23] and recently was shown to
abolish kallikrein induced activation of high molecular weight,
atrial natriuretic peptide [24]. Yet, there are several reasons for
considering a cause—effect relationship between the action of
aprotinin to suppress vasopressin induced elevation of urinary
kinins and the associated augmentation of vasopressin induced
antidiuresis. For example, kinins increase the blood flow to the
kidney [7], interfere with the tubular reabsorption of sodium
[25, 26], inhibit vasopressin—stimulated water flow in the am-
phibian urinary bladder [12] and in the rabbit cortical collecting
tubule perfused in vitro [131, and stimulate the renal synthesis
of PGE2 [271, a prostaglandin which inhibits the hydroosmotic
response of the collecting tubule to vasopressin [28, 29]. Ac-
cordingly, to the extent that renal kinins oppose the antidiuretic
effect of vasopressin at low doses, amplification of vasopressin
induced antidiuresis in rats treated with aprotinin may be a
consequence of renal kallikrein inhibition which prevents aug-
mentation of renal kinins in response to increased vasopressin
levels [10]. Our study does not support a close functional
interaction between renal kinins and PGE2 during vasopressin
administration, as the urinary excretion rate of PGE2 was
largely independent from that of kinins.
In conclusion, treatment with aprotinin amplifies the antidi-
uretic effect of vasopressin at low doses in Brattleboro rats with
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hereditary diabetes insipidus, and blunts the vasopressin in-
duced elevation of urinary kinins. The effect of aprotinin in
enhancing the antidiuretic response to vasopressin may be the
expression of reduced renal kinin levels, inhibition of renal
enzymes other than kallikrein, or other unrecognized properties
of the agent.
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